

**Kyowa Hakko Kirin Co., Ltd.****Appendix to the Fiscal 2009 Consolidated Financial Statements**

(April 1, 2009 - December 31, 2009)

	<b>Index</b>	<b>Page</b>
<b>Consolidated</b>	I. Financial results	
	1. Income	1
	2. Results by segment	1
	3. Other income	2
	4. Extraordinary income/losses	2
	5. R&D expenses	2
	6. Capital expenditure	3
	7. Depreciation expenses	3
	8. Number of staff	3
	9. Key indicators	3
	II. Subsidiaries and affiliates	4
<b>Non-Consolidated</b>	III. Net sales by division	
	1. Kyowa Hakko Kirin	5
	2. Kyowa Hakko Bio	6
	3. Kyowa Hakko Chemical	6
<b>R&amp;D Pipelines</b>		7

This document was made as a supplement to the Kessan Tanshin (financial report) for Fiscal 2009, the nine-month period from April 1, 2009 to December 31, 2009. This document contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.

## I. Consolidated Financial Results

### 1. Trends in income

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009		April 1, 2009 to December 31, 2009					(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to December 31 results (A)	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 forecasts	April 1 to December 31 results (B)	Change with previous nine-month period			January 1 to June 30 forecasts	January 1 to December 31 forecasts
						Change (B-A)	Percentage change			
<b>Net sales</b>	362,278	460,183	194,395	310,000	309,111	(53,166)	85%	407,017	200,000	400,000
<b>Gross Profit</b>	159,870	200,297	89,844	-	139,739	(20,130)	87%	180,167	-	-
Selling, general and administrative expenses	117,174	154,910	69,064	-	111,496	(5,678)	95%	149,232	-	-
Operating income (prior to amortization of goodwill)	49,893	54,983	25,431	41,977	35,221	(14,671)	71%	40,311	23,151	45,303
<b>Operating income</b>	42,696	45,387	20,779	35,000	28,243	(14,452)	66%	30,934	18,500	36,000
Other income	3,736	5,871	3,372	-	4,012	275		6,147	-	-
Other expenses	3,166	4,846	1,950	-	2,776	(390)		4,455	-	-
<b>Recurring income</b>	43,265	46,412	22,201	36,000	29,479	(13,785)	68%	32,626	19,000	37,500
Extraordinary income	-	6,075	-	-	27	27		6,102	-	-
Extraordinary expenses	13,981	21,550	1,801	-	8,878	(5,102)		16,447	-	-
<b>Net income before income taxes</b>	29,284	30,937	20,400	30,000	20,628	(8,655)	70%	22,282	17,500	36,000
Corporate, local and enterprise taxes	18,355	18,934	9,423	-	11,631	(6,723)		12,210	-	-
Income from minority interests	445	276	165	-	199	(245)		31	-	-
<b>Net income</b>	10,483	11,726	10,811	15,000	8,797	(1,686)	84%	10,040	9,500	20,000
EPS before goodwill amortization (#/share)	30.80	37.14	27.05	38.49	27.63			33.97	24.85	51.45

\*As a result of the change in fiscal year end, the fiscal period ended December 31, 2009 is for the nine-month period from April 1, 2009 to December 31, 2009 and therefore comparisons to the previous period are with the nine-month period from April 1, 2008 to December 31, 2008.

\*\* Figures in the "(Reference) January 1, 2009 to December 31, 2009 results" column have been provided as a 12-month reporting period for reference purposes and consist of the sum of the results of the consolidated fourth quarter of fiscal 2008 (the 3-month period from January 1, 2009 to March 31, 2009) and consolidated fiscal 2009 (the 9-month period from April 1, 2009 to December 31, 2009).

### 2. Trends in results by segment

#### (1) Results by operating segment

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009		April 1, 2009 to December 31, 2009					(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to December 31 results (A)	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 forecasts	April 1 to December 31 results (B)	Change with previous nine-month period			January 1 to June 30 forecasts	January 1 to December 31 forecasts
						Change (B-A)	Percentage change			
<b>Net sales</b>	362,278	460,183	194,395	310,000	309,111	(53,166)	85%	407,017	200,000	400,000
Pharmaceuticals	161,337	210,448	103,968	162,000	158,273	(3,063)	98%	207,384	102,000	205,000
Bio-Chemicals	67,545	88,464	41,417	70,000	69,751	2,205	103%	90,670	44,000	84,000
Chemicals	77,322	89,204	32,854	50,000	52,326	(24,996)	68%	64,208	59,000	121,000
Food	32,834	42,468	-	-	-	(32,834)	-	9,633	-	-
Other	54,502	68,733	28,927	48,000	49,500	(5,001)	91%	63,731	5,000	10,000
Total	393,542	499,319	207,168	330,000	329,851	(63,690)	84%	435,628	210,000	420,000
Eliminations	(31,264)	(39,135)	(12,772)	(20,000)	(20,740)	10,524	66%	(28,611)	(10,000)	(20,000)
<b>Operating income</b>	42,696	45,387	20,779	35,000	28,243	(14,452)	66%	30,934	18,500	36,000
*Before goodwill amortization	49,893	54,983	25,431	41,977	35,221	(14,671)	71%	40,311	23,151	45,303
Pharmaceuticals	29,662	34,832	21,363	33,500	26,657	(3,005)	90%	31,826	16,000	29,000
Bio-Chemicals	36,134	43,460	25,677	39,971	33,129	(3,005)	92%	40,455	20,314	37,628
	7,425	8,342	1,665	3,300	3,048	(4,376)	41%	3,965	2,000	4,000
	7,894	8,967	1,978	3,769	3,517	(4,376)	45%	4,590	2,312	4,625
Chemicals	3,532	(47)	(2,486)	(2,300)	(1,984)	(5,517)	-%	(5,564)	400	2,700
	3,569	2	(2,462)	(2,263)	(1,947)	(5,517)	-%	(5,514)	424	2,749
Food	999	1,086	-	-	-	(999)	-%	87	-	-
	1,218	1,379	-	-	-	(1,218)	-%	161	-	-
Other	1,060	1,094	170	500	400	(659)	38%	434	100	300
	1,060	1,094	170	500	400	(659)	38%	434	100	300
Total	42,680	45,308	20,712	35,000	28,122	(14,557)	66%	30,750	18,500	36,000
Eliminations	49,877	54,904	25,363	41,977	35,100	(14,777)	70%	40,127	23,151	45,303
	15	78	67	-	121	105	765%	184	-	-

1. Figures representing goodwill before amortization have been italicized.

2. The Food business segment has been excluded as of the fiscal period ended December 31, 2009. The Food business was discontinued at the end of the current consolidated fiscal year following the sale of shares of the consolidated subsidiaries that operated the businesses at the end of the previous consolidated fiscal year.

3. Results of subsidiaries Miyako Kagaku Co., Ltd., and Kashiwagi Corporation, will be reported under the Chemicals segment rather than the Other segment as of the January 1, 2010 to December 31, 2010 (Forecasts) onwards.

## (2) Overseas sales

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009				April 1, 2008 to December 31, 2009				(Reference) January 1, 2009 to December 31, 2009 results	
	April 1 to December 31 results	Percentage of consolidated sales	April 1 to March 31 results	Percentage of consolidated sales	April 1 to September 30 results	Percentage of consolidated sales	April 1 to December 31 results	Percentage of consolidated sales	January 1 to December 31 results	Percentage of consolidated sales
<b>Overseas sales</b>	74,928	20.7%	88,770	19.3%	39,725	20.4%	63,367	20.5%	77,209	19.0%
America	27,202	7.5%	31,023	6.7%	10,688	5.5%	16,849	5.5%	20,670	5.1%
Europe	18,117	5.0%	22,631	4.9%	11,309	5.8%	18,524	6.0%	23,038	5.7%
Asia	28,960	8.0%	34,254	7.4%	17,420	9.0%	27,415	8.9%	32,709	8.0%
Other regions	647	0.2%	860	0.2%	306	0.2%	578	0.2%	791	0.2%
<b>Total consolidated net sale</b>	<b>362,278</b>	<b>100.0%</b>	<b>460,183</b>	<b>100.0%</b>	<b>194,395</b>	<b>100.0%</b>	<b>309,111</b>	<b>100.0%</b>	<b>407,017</b>	<b>100.0%</b>

## 3. Trends in other income

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results	
<b>Other income</b>	3,093	3,736	5,871	3,372	4,012	6,147
Interest received	351	534	688	249	443	597
Dividend income	668	975	2,394	1,125	914	2,333
Foreign exchange gain	442	-	135	-	-	135
Income from equity method investments	694	995	1,211	945	1,558	1,774
Other	936	1,230	1,441	1,051	1,095	1,306
<b>Other expenses</b>	1,899	3,166	4,846	1,950	2,776	4,455
Interest expense	300	413	523	153	244	354
Foreign exchange loss	-	555	-	503	112	(443)
Loss from disposal of fixed assets	856	1,205	2,483	843	1,163	2,441
Other	742	991	1,839	449	1,255	2,103

## 4. Trends in extraordinary income / losses

Millions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results	
<b>Extraordinary income</b>	-	-	6,075	-	27	6,102
Gain on sale of fixed assets	-	-	-	-	27	27
Gain on sale of shares in affiliates	-	-	4,721	-	-	4,721
Gain of sale of investments in affiliates	-	-	1,354	-	-	1,354
<b>Extraordinary losses</b>	4,769	13,981	21,550	1,801	8,878	16,447
Extraordinary depreciation of fixed assets	762	762	762	-	3,299	3,299
Asset impairment losses	1,931	1,931	5,724	-	2,671	6,464
Loss from change in equity affiliates*	-	-	-	1,379	1,379	1,379
Loss from sale of investment securities	-	-	-	-	991	991
Loss from revaluation of investment securities	180	5,266	6,634	421	537	1,905
Integration-related expenses	1,895	4,084	5,514	-	-	1,429
Compensation payment	-	1,937	1,937	-	-	-
Other	-	-	977	-	-	977

\*Loss from change in equity affiliates resulted from the change in holdings of equity in affiliates following the April 1, 2009 merger of Kirin Food-Tech with Kyowa Hakko Food Specialties (now Kirin Kyowa Foods), an affiliate accounted for by the equity method.

## 5. Trends in R&amp;D expenses

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
<b>R&amp;D (Consolidated)</b>	25.9	36.9	48.3	19.7	34.9	46.4	22.2	46.4
R&D to net sales ratio (%)	10.5%	10.2%	10.5%	10.2%	11.3%	11.4%	11.1%	11.6%
Pharmaceuticals	23.0	32.5	42.6	17.5	31.6	41.6	19.7	41.5
(R&D to net sales ratio) (%)	21.2%	20.2%	20.3%	16.9%	20.0%	20.1%	19.4%	20.3%
Bio-Chemicals	1.8	2.7	3.6	1.6	2.5	3.4	1.9	3.7
Chemicals	0.5	0.8	1.1	0.5	0.7	1.0	0.5	1.0
Food	0.4	0.6	0.9	-	-	0.2	-	-
Other	0.0	0.0	0.0	0.0	0.0	0.0	-	-

## 6. Trends in capital expenditure

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
<b>Capital expenditure (Consolidated)</b>	8.5	12.9	18.4	15.3	24.0	29.6	14.4	27.8
Pharmaceuticals	3.6	5.5	9.6	9.4	15.4	19.5	7.8	15.6
Bio-Chemicals	2.0	3.8	5.3	3.3	4.9	6.4	4.5	9.6
Chemicals	2.4	2.9	4.3	2.5	3.5	4.9	2.0	2.5
Food	0.3	0.4	0.5	-	-	-	-	-
Other	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Eliminations	(0.0)	(0.0)	(1.5)	(0.0)	(0.0)	(1.5)	-	-

## 7. Trends in depreciation expenses

Billions of yen, rounded down

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
<b>Depreciation expenses (Consolidated)</b>	9.6	14.3	18.7	8.6	17.0	21.4	9.5	22.1
Pharmaceuticals	4.6	6.6	8.3	3.8	9.2	10.9	4.5	11.5
Bio-Chemicals	2.4	3.7	5.0	2.6	4.3	5.5	2.7	5.8
Chemicals	2.0	3.0	4.2	2.1	3.3	4.4	2.2	4.7
Food	0.4	0.7	0.9	-	-	0.2	-	-
Other	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0
Eliminations	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	-	-

## 8. Trends in number of staff

Number of people

	April 1, 2008 to March 31, 2009	April 1, 2009 to December 31, 2009	Change (B-A)
	Results (A)	Results (B)	
<b>Number of staff at end of term</b>	7,256	7,436	180
Pharmaceuticals	4,594	4,718	124
Bio-Chemicals	1,528	1,580	52
Chemicals	514	520	6
Other	326	319	(7)
Whole company (combined)	294	299	5

## 9. Trends in key indicators

(1) Exchange rate

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009		(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
US Dollar (¥US\$)	106	103	101	96	94	94	91	91
Euro (¥Euro)	163	151	143	133	133	130	133	133

(2) Operating indicators (Consolidated)

	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 results
(prior to amortization of goodwill)	22.79	30.80	37.14	27.05	27.63
Net income per share (yen)	14.43	18.26	20.43	18.91	15.41
Operating income to sales ratio (%)	11.8	11.8	9.9	10.7	9.1
Total assets (million yen)	748,454	725,893	699,041	716,199	695,268
Net assets (million yen)	551,817	544,037	543,070	547,942	540,343
Equity ratio (%)	73.1	74.3	77.0	75.9	77.1
Net assets per share (yen)	952.77	939.72	938.42	953.91	940.79
ROIC (Return on invested capital)*	8.2	12.1	14.5	6.6	9.2

$$* \text{ROIC} (\%) = \frac{\text{Operating income}}{(\text{Fixed assets} + \text{Working capital})} \times 100$$

Calculations for operating income are prior to amortization of goodwill and calculations for fixed assets do not include goodwill

## II. Subsidiaries and affiliates

(As of December 31, 2009)

Segment	Type	Company name	Percentage owned (direct and indirect)	Principal business
Pharmaceuticals	Consolidated subsidiary	Kyowa Medex Co., Ltd.	100.0%	Manufacture and sale of diagnostic reagents
		Kirin Kunpeng (China) Bio- Pharmaceutical Co., Ltd.	70.0%	Manufacture and sale and of pharmaceuticals (China)
		Kyowa Medical Promotion Co., Ltd.	100.0%	Sales promotion of pharmaceuticals
		Kyowa Hakko Kirin America, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		BioWa, Inc.	100.0%	Out-licensing and promotion of anti-body technology (US)
		Kyowa Hakko Kirin Pharma, Inc.	100.0%	Development of outsourced pharmaceutical products
		Kyowa Hakko Kirin California, Inc.	100.0%	Generate new candidate substances and develop pharmaceuticals (US)
		Hematech, Inc.	100.0%	Technology research for manufacture of therapeutic antibody (US)
		Hematech-GAC Venture, LLC	51.0%	Technology research for manufacture of therapeutic antibody (US)
		Jeil-Kirin Pharmaceutical Inc.	90.0%	Sales of pharmaceuticals (Korea)
		Kyowa Kirin Pharmaceuticals (Taiwan) Co., Ltd.	100.0%	Sales of pharmaceuticals (Taiwan)
		Kyowa Hakko Kirin (Hong Kong) Co., Ltd.	100.0%	Sales of pharmaceuticals (Hong Kong)
		Kyowa Hakko Kirin (Singapore) Pte. Ltd.	100.0%	Sales of pharmaceuticals (Singapore)
Bio-Chemicals	Consolidated subsidiary	Kyowa Hakko Bio Co., Ltd.	100.0%	Manufacture and sale of pharmaceutical and industrial raw materials, and health care products
		Daiichi Fine Chemical Co., Ltd.	100.0%	Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates
		Biokyowa Inc.	100.0%	Manufacture and sale of amino acids (US)
		Shanghai Kyowa Amino Acid Co., Ltd.	70.0%	Manufacture and sale of amino acids (China)
		Kyowa Hakko U.S.A., Inc.	100.0%	Sale and import/export of fine chemicals including amino acids (US)
		Kyowa Hakko Europe GMBH	100.0%	Sale and import/export of fine chemicals including amino acids (Germany)
		Kyowa Italiana Farmaceutici S.R.L.	100.0%	Sale and import/export of fine chemicals including amino acids (Italy)
		Kyowa Hakko (H.K.) Co., Ltd.	100.0%	Sale and import/export of fine chemicals including amino acids (Hong Kong)
		Kyowa Hakko Bio U.S. Holdings, Inc.	100.0%	Holding company for administration and management of US subsidiaries (US)
		Kyowa Wellness Co., Ltd.	100.0%	Sale of healthcare products
		Shinwa Pharmaceutical Co., Ltd.	100.0%	Sale of herbal medicines and health foods
Kyowa Engineering Co., Ltd.	100.0%	Design and installation of plant facilities and equipment		
Chemicals	Consolidated subsidiary	Kyowa Hakko Chemical Co., Ltd.	100.0%	Manufacture and sale of chemicals
	Affiliate accounted for by the equity method	J-PLUS Co., Ltd.	50.0%	Manufacture and sale of plasticizers
		Kurogane Kasei Co., Ltd.	40.0%	Manufacture and sale of plasticizers, fine chemicals, etc.
Other	Consolidated subsidiary	Miyako Kagaku Co., Ltd.	52.9%	Wholesale sales of pharmaceutical raw materials, chemicals, foods, etc.
		Chiyoda Kaihatsu Co., Ltd.	100.0%	Transportation, insurance, wholesale sales of food, etc.
		Kashiwagi Corporation	62.9%	Wholesale sales of chemicals, food, etc.
	Affiliate accounted for by the equity method	Japan Synthetic Alcohol Co., Ltd.	33.3%	Manufacture and sale of industrial use alcohol
		Kirin Kyowa Foods Company, Limited	35.0%	Manufacture and sale of seasonings, confectionery and bread products
		Kyowa F.D. Foods Co., Ltd.	35.0%	Manufacture and sale of freeze-dried foods
		Ohland Foods Co., Ltd.	35.0%	Manufacture and sale of bakery products, etc.
		Kyowa HiFoods Co. Ltd.	35.0%	Import and sale of foods, etc.
		Aji-Nihon Co., Ltd.	16.2%	Manufacture and sale of foods and seasonings, etc.
Zenmi Foods Inc.	17.5%	Manufacture and sale of seasonings		

### 1. Changes to the scope of consolidation

Newly consolidated: One company: Kyowa Hakko Kirin Pharma, Inc.

Eliminated One company: Kyowa Hakko Kirin (Thailand) Co., Ltd.

### 2. As of fiscal 2010, the classification of Miyako Kagaku Co., Ltd. and Kashiwagi Corporation be changed from the Other segment to the Chemicals segment

3. On January 1, 2010, Kyowa F.D. Foods Co., Ltd. and Ohland Foods Co., Ltd. will change their company names to Kirin Kyowa FD Co., Ltd. and Kirin Ohland Foods Co., Ltd. respectively

### III. Net sales by division (Items and main products presented on a non-consolidated basis)

#### 1. Kyowa Hakko Kirin

Billions of yen, rounded down

Pharmaceuticals division (non-consolidated)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009			(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 forecast (Oct. 29)	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
Pharmaceutical division total	99.2	147.5	191.3	94.9	146.8	143.9	187.6	93.9	188.6
Central nervous system agents									
<i>Depakene</i>	5.3	8.3	10.7	5.7	8.8	8.8	11.2	5.3	11.0
<i>Topina</i>	0.3	0.6	0.9	0.8	1.1	1.2	1.5	0.9	1.9
Sensory organ agents									
<i>Patanol</i>	1.4	2.2	6.6	1.9	3.2	3.0	7.4	5.3	7.9
Circulatory organ agents									
<i>Coniel</i>	11.6	18.1	23.1	11.7	18.0	18.3	23.3	10.6	21.3
<i>Inovan / Pre Dopa</i>	1.8	2.9	3.7	1.7	2.7	2.7	3.5	1.6	3.3
<i>Coversyl</i>	2.6	4.0	5.0	2.4	3.6	3.7	4.8	2.2	4.4
Digestive organ agents									
<i>Nauzelin</i>	2.4	4.2	5.5	2.4	4.2	3.8	5.1	2.5	5.3
Other metabolic medicines									
<i>Nesp/Espo</i>	21.3	34.4	43.7	25.7	40.0	39.6	48.9	25.2	49.7
<i>Regpara</i>	1.9	3.3	4.6	3.4	5.0	5.5	6.8	3.6	7.3
Blood and humoral applications									
<i>Gran/Neu-up</i>	9.1	14.3	17.6	8.9	14.0	13.8	17.0	7.0	15.1
Anticancer agents									
<i>Farmorubicin / Adriacin</i>	3.8	5.9	7.4	3.3	5.1	4.9	6.4	2.8	5.5
<i>5 - FU (all types)</i>	1.8	2.8	3.6	1.9	2.8	2.9	3.7	1.4	2.7
<i>Navelbine</i>	1.5	2.4	3.1	1.5	2.3	2.2	2.9	1.3	2.6
Antiallergic agents									
<i>Allelock</i>	9.6	15.6	25.0	10.9	17.0	17.3	26.7	14.2	26.0
<i>Celtect</i>	1.7	2.6	3.6	1.5	2.2	2.3	3.3	1.5	2.7
Exports and Technology Out-Licensing	22.8	26.3	29.1	11.7	14.7	15.1	18.0	12.2	22.6

Note 1: Figures until September 30 of the fiscal year ending March 31, 2009 are the combined unit sales of the former Kirin Pharma and the former Kyowa Hakko Kogyo.

Note 2: Results based on settlement price on a shipment basis. Forecasts are based on an actual consumption basis.

## 2. Kyowa Hakko Bio

Billions of yen, rounded down

Bio-Chemicals division (non-consolidated)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009			(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 forecast (Oct. 29)	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
<b>Bio-Chemical division total</b>	28.4	42.1	55.2	27.0	40.3	42.3	55.4	27.7	52.2
<b>Pharmaceuticals / Industrial raw materials</b>									
<b>Amino acids</b>	10.2	14.9	19.3	9.4	14.1	14.8	19.1	10.0	19.5
<b>Nucleic acids and vitamins</b>	2.9	4.0	5.0	2.1	3.0	3.5	4.5	2.4	4.9
<b>Health care products</b>	4.2	6.2	8.1	4.2	6.3	6.5	8.4	4.4	9.0
<b>Agrochemicals, livestock and fisheries products</b>	1.6	2.5	3.6	1.5	2.4	2.1	3.2	1.5	1.9
<b>Alcohol</b>	4.6	7.2	9.3	4.8	6.8	7.8	9.8	4.7	7.6

1. Figures until September 30 of the fiscal year ending March 31, 2009 are those of the Bio-Chemicals division of Kyowa Hakko Kogyo.

3. On April 1, 2010, Kyowa Hakko Bio Co., Ltd. domestic sales operations for agrochemicals, livestock and fisheries is scheduled to be assigned to ASKA Pharmaceutical Co., Ltd.

2. On July 1, 2010, the Kyowa Hakko Bio Co., Ltd. alcohol business is scheduled to be transferred to a joint venture with Mercian Corporation and Daiichi Alcohol Co. (planned investment ratio: 35%).

## 3. Kyowa Hakko Chemical

Billions of yen, rounded down

Chemicals division (non-consolidated)  (Kyowa Hakko Chemical Co., Ltd.)	April 1, 2008 to March 31, 2009			April 1, 2009 to December 31, 2009			(Reference) January 1, 2009 to December 31, 2009 results	January 1, 2010 to December 31, 2010	
	April 1 to September 30 results	April 1 to December 31 results	April 1 to March 31 results	April 1 to September 30 results	April 1 to December 31 forecast (Oct. 29)	April 1 to December 31 results		January 1 to June 30 forecasts	January 1 to December 31 forecasts
<b>Chemical division total</b>	57.1	77.3	89.2	32.8	50.0	52.3	64.2	38.3	80.3
<b>Solvents</b>	25.5	35.0	39.7	14.5	22.0	22.6	27.2	16.9	35.1
<b>Raw materials for plasticizers</b>	19.7	25.9	29.4	9.9	16.5	16.3	19.8	11.5	24.8
<b>Specialty chemicals</b>	9.7	13.2	16.4	6.8	11.0	11.3	14.5	8.8	18.2

## R&D PIPELINES

Phase / Phase

January 29, 2010

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Remarks
		Japan	Other countries				
Cancer/ Hematology	KW-0761	Phase	Phase / a in USA	Cancer (Hematologic tumor)	Injection	Developed In-house	Humanized monoclonal antibody
	KRN321 Nesp	Filed Nov/2008		Chemotherapy induced anemia	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein An approval has been given in Japan for anemia of CKD patients on dialysis.
	AMG531	Phase		Immune thrombocytopenic purpura	Injection	Kirin-Amgen	Thrombopoiesis stimulating peptibody Clinical development is being conducted by Amgen Development KK as per agreement
	KW-2246	Phase		Cancer pain	Sublingual tablet	Licensed from Orexo	
	KRN125	Phase		Neutropenia	Injection	Kirin-Amgen	Long-acting G-CSF
Kidney	PB94 PHOSBLOCK (RENAGEL)		Filed in China Jun/2008	Hyperphosphatemia	Oral	Licensed from Chugai	Launched in Japan
	KRN321 Nesp	Filed Dec/2008	Phase in China	Anemia (not on dialysis) Anemia (on dialysis)	Injection	Kirin-Amgen	Long-acting erythropoiesis stimulating protein An approval has been given in Japan for anemia of CKD patients on dialysis
Immunology/ Allergy	KW-4679 ALLELOCK		Filed in China Jul/2008	Allergy	Oral	Developed In-house	Launched in Japan
	Z-206 ASACOL	Phase		Inflammatory bowel disease (Crohn's disease)	Oral (pH depend controlled-release formulation)	Licensed from Zeria Pharma.	Jointly developed with Zeria Pharma
CNS	KW-6002	Phase	Filed in USA Apr/2007	Parkinson's disease	Oral	Developed In-house	
	KW-6500	Phase		Parkinson's disease	Injection	Licensed from Britannia Pharma	

### Phase

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Remarks
		Japan	Other countries				
Cancer/ Hematology	KW-2450		Phase in USA	Cancer	Oral	Developed In-house	
	KRN654	Phase /		Essential thrombocythemia	Oral	Licensed from Shire	
	KW-2449		Phase / a in USA	Cancer	Oral	Developed In-house	
	KW-2478		Phase in Europe	Cancer	Injection	Developed In-house	
	ARQ 197	Phase		Cancer	Oral	Licensed from ArQule	
	KRN330		Phase / a in USA	Cancer	Injection	Developed In-house	Fully human monoclonal antibody
	BIW-8962		Phase / a in USA	Cancer	Injection	Developed In-house	Humanized monoclonal antibody
	KRN951	Phase		Cancer	Oral	Developed In-house	
Immunology/ Allergy	ASKP1240		Phase	Organ Transplant Rejection	Injection	Developed In-house	Fully human monoclonal antibody Jointly developed with Astellas Pharma Inc.
Other	KW-3357	Phase	Phase in Europe	Disseminated intravascular coagulation, Congenital antithrombin deficiency	Injection	Developed In-house	Recombinant antithrombin product
	KRN23		Phase in USA	Hypophosphatemic disease such as X-linked Hypophosphatemia (XLH)	Injection	Developed In-house	Fully human monoclonal antibody

(Note)

In the Philippines, application for approval has been filed for Filgrastim (G-CSF)

In Thailand, Singapore, Malaysia and the Philippines, approval for Nesp (Long-acting erythropoietin stimulating protein) has been filed. In Korea, Taiwan and Hong Kong Nesp has been approved.

In Korea and Taiwan application for approval of Regpara (Calcimimetic agent) has been filed. In Macau and Hong Kong, Regpara has been approved.

Updated since October 29, 2009 (Area, Stage, Filed, Approved, Launched etc.)  
New indication

### Discontinued

Category	Code Name Product Name	Stage		Indication	Formulation	In-house or licensed	Reason
		Japan	Other countries				
Cardiovascular	NU206		Phase in Australia	Inflammatory bowel disease	Injection	Developed with ARCA biopharma (the former Nuvelo )	Portfolio review
	AGS-003		Phase in USA and Canada	Renal Cell Carcinoma	Injection	Developed with Argos	Portfolio review
	AGS-004		Phase in USA and Canada	HIV	Injection	Developed with Argos	Portfolio review